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ABSTRACT
The majority of cases of allergic asthma in experi-
mental animals have been provoked by inhalation 
with mist antigen. Because of the inherent inability of 
some species to breathe through the mouth, including 
guinea pigs, mice and rats, an upper airway response 
may be substantially involved in experimental asthma 
induced by antigen inhalation. With this in mind, we 
evaluated three types of nebulizers (a hand-made 
glassware pressure nebulizer (GPN), a DeVilbiss 
nebulizer (DN) and an ultrasonic nebulizer (UN)) with 
respect to their ability to adequately 
sensitize/challenge guinea pigs by antigen inhalation 
in bronchial asthma. Several solutions and 
suspensions, including antigen and Al(OH)3, were 
atomized with these three nebulizers. The results 
obtained were as follows: irrespective of the type of 
solution or suspension used, of the three nebulizers, 
GPN generated mists with the smallest diameter. The 
rank order of median diameter of the mists generated
was GPN (1.6-2.1μm)<DN (2.2-3.5μm)<UN
(4.3-4.7μm). When Evans blue mists produced by
the GPN were presented to guinea pigs, 79% of the 
mist trapped in the whole airway was found in the 
lung, while 49 and 79% of mists produced by DN and 
UN, respectively, were already deposited in the upper 
airway. These results strongly suggest that GPN is 
more useful for inhalation challenge in experimental 
asthma in animals.
Key words: allergy, aluminum hydroxide, antigen 
mist, asthma, inhalation, nebulizer, sensitization.
INTRODUCTION
Several experimental models have been developed for 
the study of asthma, particularly the late and early 
asth atic responses (LAR and EAR, respectively).1-10 
Guinea pigs have long been preferentially used as good 
animal models of asthma because their airway smooth 
mu cle responsiveness to many biologically active 
compounds is very similar to that seen in humans.11,12 In 
addition, guinea pigs have been shown to exhibit both 
EAR and LAR after antigen challenge,4-6,13-15 In animal 
models with a dual asthmatic response, guinea pigs are 
sensitized and challenged with aerosolized antigen. 
However, guinea pigs breathe through the nose and 
never through the mouth. Therefore, inhaled mists may 
be trapped in the upper airway to some degree, 
consequently suggesting that nasal airway resistance is 
involved in airway dysfunction, which was thought to 
have been due to a decrease of lung compliance or an 
increase of airway resistance in response to the inhalation 
challenge. Indeed, it has been reported that the LAR in 
guinea pigs16 as well as the EAR in rats17 are composed of 
both upper and lower airway responses. These reports 
suggest that in experimental asthmatic animal models, 
the antigen-antibody reaction should be induced in the 
lower airway as much as possible. 
 In contrast, aluminum hydroxide gels (Al(OH)3) have 
been frequently used as an adjuvant for IgE production by 
intraperitoneal injection with antigen in animals.15,18,19 We 
aimed to sensitize guinea pigs by repetitive exposure of 
the animals to mist of antigen adsorbed onto Al(OH)3, 
taking into account its adjuvant properties. However, 
there are no reports to date on whether the adjuvant gel
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suspension is able to be effectively aerosolized and 
whether the generated mist is sufficiently adsorbed in the 
airway of guinea pigs. 
 In the present study we evaluated three kinds of 
nebulizers, including a hand-made glassware pressure 
nebulizer (GPN), a DeVilbiss nebulizer (DN) and an 
ultrasonic nebulizer (UN), for adequate antigen and 
Al(OH)3/antigen inhalation to sensitize/challenge.
METHODS
Animals
Male 3-week-old Hartley guinea pigs, weighing 250-
300g, were purchased from Japan SLC (Hamamatsu, 
Japan).
Reagents
Reagents and their sources were as follows: ovalbumin 
(OA) and NaCl (Wako Pure Chemicals, Osaka, Japan); 
Evans blue dye (Merck, Darmastadt, Germany); heparin 
sodium (Takeda Chemical Industries, Osaka, Japan); 
and sodium pentobarbital (Abbott Laboratories, North 
Chicago, IL, USA). The other reagents used were the 
highest grade of commercial products available.
Preparation of aluminum hydroxide gel
The Al(OH)3 was prepared by instilling 0.5mol/L NaOH 
(100L) to 0.5mol/L Al2 (SO4)3 (100L) with vigorous 
stirring; these concentrations were lower than those 
reported by Levine et al.18 The Al(OH)3 was washed three 
times with water purified by double distillation 
(Barnstead, Dubuque, IA, USA) and the Milli Q system 
(Millipore, Bedford, MA, USA). The average diameter of
the gel particles was 0.43μm when measured by a laser
diffraction particle size analyzer (SALD-2000A; 
Shimadzu, Kyoto, Japan) for the distribution of particle 
size. The gel was divided and stored at a concentration of 
60mg/mL physiological saline in sealed bottles (300
mL/bottle) at 4℃ until use.
Preparation of OA+Al(OH)3 and Evans blue+
Al(OH)3
One volume of 2.4mg/mL OA was instilled into 2 
volumes of 60mg/mL Al(OH)3 suspension under stirring
to make a concentration of 800μg OA/40mg Al(OH)3
per mL [OA+Al(OH)3]. Evans blue+Al(OH)3 was 
prepared in the same manner as OA+Al(OH)3 at a
concentration of 5mg Evans blue/40mg Al(OH)3 per 
mL. A  these concentrations, OA and Evans blue were 
completely adsorbed onto the gel. Solutions of 5mg 
Evans blue/mL (Evans blue) in saline, 16mg OA/mL 
(OA) in saline and saline were also prepared.
Mist generation with the nebulizers and 
inhalation of the mists in the guinea pig
Hand-made glassware pressure nebulizer
As illustrated in Fig. 1, the solution or suspension 
(approximately 50mL) was placed in a 2L transparent 
flask made of polyvinyl chloride, in which the head of the 
nebulizer was set through a plug, and was supplied to the 
nebulizer and circulated with a peristaltic pump (MP-3; 
Eyela, Tokyo, Japan) at a flow rate of 10mL/min under 
stirring. The pressurized air was also supplied to the 
nebulizer under 101kPa and 11.4L air/min. The mists 
were first introduced into a polypropylene box (1.6L 
volume) for the elimination of relatively large particle 
mists and then guinea pigs were forced to inhale the mists 
under pentobarbital anesthesia (30mg/kg, i. p.).
DeVilbiss nebulizer
Following placement of the solution or suspension in the 
bottom of the DN (Pulmo Neb; DeVilbiss, Somerset, PA, 
USA), air pressurized by an air pump (Pulmo Aide; 
DeVilbiss) was supplied to the nebulizer at a flow rate of 
7.9L air/min. Anesthetized guinea pigs were set in the 
two-chambered box, comprising a head and body 
compartment, and were forced to inhale the generated 
mists.
Ultrasonic nebulizer
Antigen, Evans blue or vehicle solution mists produced by 
the UN (NE-U12; Omron, Tokyo, Japan) were 
introduced to the head compartment of the two-
chambered box, in which the anesthetized guinea pig 
was placed, with aeration at a rate of 2.0L/min. 
 In order to determine the airway distribution of the 
mists produced by the different nebulizers, Evans blue dye 
was used as a marker in place of the antigen. Guinea 
pigs were exposed to mists of either Evans blue + 
Al(OH)3 or Evans blue alone generated by the three
nebulizers at 100μg Evans blue/animal; the
concentration of Evans blue dye was calculated on the 
basis of respective mist concentrations produced by the
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Fig. 1 Schematic illustration of the experimental apparatus for the inhalation of antigen mists generated with a hand-made 
glassware pressure nebulizer (GPN) in the guinea pig. The conditions for generating mists were air flow rate 11.4L air/min 
(at 101kPa) and micro tube pump flow rate 10mL/min.
nebilizers and the respiratory volume of the animal for 1 
min, which was measured by a two-chambered, double-
flow plethysmograph system (Pulmos-I; MIPS, Osaka, 
Japan).
Measurement of mist particle diameter
The respective mass median diameters of the various 
mists produced with the three nebulizers were measured 
by a laser diffraction size analyzer (LDSA-1400A; Tohnichi 
Computer Applications, Tokyo, Japan).
Measurement of mist concentration
For measurement of mist concentrations in air of Evans 
blue+Al(OH)3 or Evans blue alone produced by the
nebulizers, 400mL (40mL×10 times) of air was
collected, at the same position where guinea pigs inhaled 
the mists, in a 50mL syringe that had been filled with 10 
mL of a mixture of acetone and 0.6mol/L phosphoric 
acid (13:5): After collection of 40mL mist air and 
vigorous shaking, the air was expelled. This manner was 
repeated 10 times. The dye dissolved in the mixture was 
colorimetrically measured at 620nm for estimation of 
mist concentration.
Determination of the amount and the 
istribution of mists trapped in the airway
After inhalation of the mist, animals were killed under 
pentobarbital anesthesia (40mg/kg, i. v.) and the upper 
(nasal cavities/pharynges) and the lower (tracheas/main 
bronchi and lungs) airway tissues were removed. The 
trapped dye in the airways was measured as described 
above following extraction according to the method of 
Katayama et al.20
RESULTS
Diameter of mists of various suspensions and 
solutions
Tabl  1 shows the median diameters of mists generated 
from the various solutions and suspensions using the 
three different nebulizers (GPN, DN and UN). Irrespective 
of t e presence of Al(OH)3, GPN produced small mists
with median particle diameters of 1.6-2.1μm. The DN
generated a 1.3- to 1.8-fold larger mist with a median
pa ticle diameter of 2.2-3.5μm.In contralst, mists of
solutions produced by the UN had the largest diameters
(4.3-4.7μm).The UN is theoretically unable to atomize
the Al(OH)3 suspension. In actual fact, it could not
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generate a mist containing Al(OH)3 even when a much 
lower concentration of the gel suspension (5mg 
Al(OH)3/mL) was used. From the results obtained with the 
GPN and DN, it is likely that the concentration or the 
viscosity of solutions can affect the diameter of the mists 
formed.
Mist concentration in the air of Evans blue + 
Al(OH)3 and Evans blue
The concentration of the Evans blue+Al(OH)3 mist
generated by the GPN was estimated at 37μg Evans
blue or 300μg Al(OH)3/L air, which was almost the
same as that of Evans blue in terms of the dye 
concentration, indicating that the GPN produced a mist 
containing the same ratio of Al(OH)3/H2O as that to be 
atomized. Furthermore, Evans blue+Al(OH)3 was
Table 1. Median diameter of mists of various solutions and 
suspensions atomized with the hand-made glassware pressure 
nebulizer (GPN), the DeVilbiss nebulizer (DN) or the ultrasonic 
nebulizer (UN)
  Concentrations of solutions or suspensions are as follows: oval-
bumin (OA), 16mg/mL; Al(OH)3, 40mg/mL; OA+Al(OH)3, 0.8mg 
OA/40mg Al(OH)3 per mL; Evans blue, 5mg/mL; Evans blue+ 
Al(OH)3, 5mg Evans blue/40mg Al(OH)3 per mL. 
  ND, not determined.
atomized at a constant concentration by the GPN for at 
least 3h continuous operation (data not shown). 
Alt ough the DN could also atomize the Al(OH)3 gel 
suspension, the mist concentration was only 
approximately 60% of that of GPN. In addition to this and 
in contrast to the GPN, DN more easily nebulized the 
solution rather than the Al(OH)3 suspension. However, 
the concentration of Evans blue mist generated with the 
UN was 10-fold higher than generated with the GPN 
(Table 2).
Amount and distribution of Evans blue+
Al(OH)3 and Evans blue alone in the airways
Table 3 shows the amount of mist trapped in the whole 
airway and its distribution in the upper and lower airways 
when guinea pigs were exposed to mists of Evans blue+
Table 2. Concentration of mists of Al(OH)3-adsorbed Evans 
blue (Evans blue+Al(OH)3) or Evans blue atomized with the 
hand-made glassware pressure nebulizer (GPN), the DeVilbiss 
nebulizer (DN) and the ultrasonic nebulizer (UN)
  Evans blue+Al(OH)3 suspension or Evans blue solution to 
be atomized was 5mg Evans blue/40mg Al(OH)3 per mL or
5mg/mL, respectively. Each value represents the mean±SE of
three experiments.
Table 3. Distribution of the mists of Al(OH)3-adsorbed Evans blue (Evans blue+Al(OH)3) or Evans blue atomized with the 
hand-made glassware pressure nebulizer (GPN), the DeVilbiss nebulizer (DN) and the ultrasonic nebulizer (UN) into the upper and 
lower airways in the guinea pig
  Guinea pigs inhaled mists of Evans blue+Al(OH)3 and Evans blue at 100μg Evans blue/800μg Al(OH)3 per animal and 100μg Evans
blue/animal as calculated doses, respectively, under pentobarbital(30mg/kg, i. p.) anesthesia. Each value represents the mean±SEM of 4-6
animals.
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Al(OH)3 or Evans blue alone generated by the nebulizers
at a dose of 100μg dye/animal. The Evans blue+
Al(OH)3 mist generated by the GPN was deposited in the 
whole airway by 66% of the expected amount, while in 
Evans blue mist with the same nebulizer, 38% of that was 
found. As for the distribution, considerable amounts of the 
dye were located in the lung: approximately 60% of the 
total amount trapped for the Evans blue+Al(OH)3 mist 
and 80% for Evans blue alone. The rest of the mist was 
found in the upper airway, nasal cavities and pharynges. 
In the case of mists generated by the DN, mists of both the 
solution and the suspension were more effectively 
captured in the whole airway than were the mists 
produced by the GPN. However, approximately
≧50% of the mist by the DN was already trapped in the
upper airways. Furthermore, Evans blue mists produced 
by the UN were most effectively deposited throughout the 
whole airway compared with mists generated by the other 
two nebulizers, but only 20% of the mists generated by the 
UN were located in the lung. For all mists produced by all 
nebulizers, only a minimal amount was located in the 
trachea and the main bronchi.
DISCUSSION
In experimental models of asthmatic responses induced 
by the inhalation of an antigen, spontaneously breathing 
animals are allowed to inhale the antigen through the 
nasal cavity, unless specific treatment is administered. 
Therefore, under these conditions, it is considered that 
increases in airway resistance or decreases of lung 
compliance following the inhalation of antigen, which 
have been assumed as indexes of bronchial asthma, may 
include nasal resistance. In the present study, we 
quantitatively evaluated the usefulness of three types of 
nebulizers with regard to mist generation, mist particle 
diameter and the way in which the mist reaches and is 
trapped in the lower airway. 
 Prior to examination, Al(OH)3, prepared from NaOH 
and Al2(SO4)3 solutions by routine methods, was 
scrutinized to determine whether the suspended gel was 
effectively atomized with a pressure nebulizer. The results 
did not come up to our expectations because the Al(OH)3 
mist had a tendency to drop for the larger sizes of gel 
particles. We overcame this problem by preparing fine 
particles of Al(OH)3 by instilling low concentrations of 
NaOH into low concentrations of Al2(SO4)3 with vigorous 
stirring. 
 The rank order diameter of the mist generated by the
nebulizers was GPN<DN<UN, irrespective of the 
presence of Al(OH)3 in the solutions to be atomized, while 
UN was unable to produce Al(OH)3 mists. When spon-
taneously breathing guinea pigs were exposed to these 
mists, the mists had a tendency to be trapped in the upper 
airway in proportion to the mist particle diameter. With 
regard to mist deposition in the whole airway, Evans blue 
+Al(OH)3 and Evans blue mists generated by the GPN 
were trapped in the whole airway by approximately 65 
nd 40%, respectively. It could be presumed that mist 
trapped in the airway was conveyed to the digestive 
organs by ciliary movement. However, no detectable 
amount of dye was found in the mouth, esophagus or 
stomach. Therefore, it could be that a mist with a small 
particle size inhaled into the airway is exhaled again 
without coming into contact with the airway mucosal 
membrane. It can be conceived that relatively large mists 
gen rated by the DN and UN were easily trapped by the 
nasal mucosa and once they were trapped, they induced 
the further accumulation of newly inhaled mists in the 
asal cavity because of a decreasing patency of the 
upper airway cavity. This suggests that if these two 
nebulizers are to be used for the induction of 
experimental asthma by a definite dose of antigen, 
inhalation with antigen mists at a high concentration over 
a short period of time provides better conditions for 
antigen inhalation than do relatively low concentrations 
for a long period of time. 
  For generating fine mists at a constant concentration 
with GPN, at least three points, described below, are 
important: (i) when air is supplied to the air nozzle of the 
GPN, a considerable flow rate (11.4L air/min in the 
present study) is required under a constant pressure (101 
kPa in the present study); (ii) a constant supply rate of 
solutions or suspensions to be atomized to the air nozzle 
is ne essary; and (iii) a box should be set between the 
nebulizer and the inhalation box to trap large mists. 
  Interestingly, as seen for DN and particularly GPN, a 
considerable difference was noted either in the amount of 
mist trapped in the whole airway or in the distribution of 
th  mist trapped in the upper and the lower airways 
between Evans blue+Al(OH)3 and Evans blue mists. As 
the median diameters of the mists between the 
uspension and solution were quite similar, these 
differences cannot be due to mist particle size. It is 
conceivable that the suspension mist has more of a 
chance to collide against the airway mucosal membrane 
because of the higher density of the Al(OH)3 mist than the 
solution mist.
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 With regard to the diameter of mist, the mean size of 
aerosol particles generated with the UN and measured 
by a particle size measurement system21 identical to that 
used in the present study has been reported to be 4.9
μm,13 which is similar to our present value. As shown in
the present experiments, the mist generated with the UN 
was deposited in the upper airway four-fold more than in 
the lower airway. Thus, it is strongly suggested that in both 
EAR and LAR observed in guinea pig asthma models 
induced by inhalation with UN-generated antigen 
mists,13-15 changes of the patency of the upper airway 
cavity are involved in EAR and LAR. In fact, there are 
reports that the upper airway contributes to LAR in guinea 
pigs after inhalation with aerosolized antigens from the 
nose16 and that challenge by topical instillation of antigen 
solution into the nostril comes in two waves (at 10min 
and 6h) of increases of nasal airway resistance.22 
Similarly, recent experiments in our laboratory have 
indicated that challenge by inhalation with Japanese 
cedar pollen, more than 99.999% of which was located 
in the upper airway,23 induced dual responses of the 
upper airway (T Nabe et al., unpubl. obs., 1997). Taking 
these results and the results of the present study into 
consideration, the efficient distribution of antigen mists to 
the lower airway is crucial for research into asthma using 
experimental animals. 
 Taking into consideration the fact that it is important 
that sufficient concentrations of antigen mists reach the 
lower airway at the time of challenge rather than at 
sensitization, it would seem that location of Al(OH)3 mists 
high in the upper airway is not an issue because Al(OH)3 
may not be used at the time of challenge. 
 We have examined whether experimental asthma is 
able to be induced by sensitization/challenge by 
repeated inhalations with GPN- and UN-generated mists
of OA solution at 20μg/animal, once every 2 weeks,
which is a considerably low dose compared with that 
used in other reports.4-6,3-15 Consequently, EAR but not
LAR emerged in guinea pigs exposed†o GPN-generated
mists, With increases of serum titers of not only γ1 but
also IgE.24 Meanwhile, repeated inhalations of the UN-
generated mists failed to induce any responses (data not 
shown). In contrast, when OA+Al(OH)3 GPN-generated 
mists were inhaled for sensitization, both EAR and LAR 
were observed.24 Therefore, it appears that the pro-
duction of anaphylactic antibodies is preferentially 
induced by antigen reaching the lower airway, even at 
relatively low doses, and that Al(OH)3 plays some role in 
the occurrence of LAR.
 In summary, it is concluded that the GPN is 
pr ferentially useful for inhalation sensitization and 
particularly for challenge in experimental animals on the 
asis of the facts that: (i) the mist produced by the GPN 
effectively reaches the lung and settles there; and (ii) the 
GPN can generate a mist of relatively high and constant 
concentration over several hours.
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